VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
MedTech & Diagnostics

AngioDynamics Executive Compensation (FY26)

ANGO · Executive and director compensation, fiscal 2022 to 2026
Chief executive, fiscal 2026
◇
James Clemmer
Latest say-on-pay support
=
November 10, 2025
Chief executive pay ratio
◇
To the median employee
Free for 3 days · no card

See how AngioDynamics’s pay stands against its peers

  • AngioDynamics's company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Where AngioDynamics sits against its disclosed peer group, with custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ANGOSee the plan and pricing
No card. Nothing is charged, and the trial ends on its own. After the trial: $499/month, or $5,000/year, about two months free.
Velarion Intel, $499/month, or $5,000/year, about two months free: one seat · every company we cover · 7-day refund, with dashboards, peer screens and board-ready briefs.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on AngioDynamics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$299 for the Executive Compensation Report. Both reports for $449.
Get the executive briefGet the board briefNo account needed.
Data as of November 11, 2026Latest filing (DEF 14A): October 8, 2026
13 filings cited on this page
If a report fails to generate we keep working until you have it. No refunds on one-time reports.
Published by Velarion Company Intelligence
AngioDynamics brief$299Get the executive brief
Velarion Intel, one year, every company
351 figures on this page: 341 cited to the filing that reported them, 10 calculated from figures it prints. See the citations

More on AngioDynamics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2025 to fiscal 2026
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — James Clemmer: $5,494,285 → $6,060,145 (10.3% higher)
CEO pay ratio: 44:1 → 45:1 (2.3% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is AngioDynamics' chief executive and what were they paid?
James Clemmer, President, CEO, received $6,060,145 in total compensation for fiscal 2026. Compared with the $5,494,285 reported for fiscal 2025, Clemmer's total was 10.3% higher.
What was AngioDynamics' say-on-pay result?
Shareholders recorded 93.2% support for the say-on-pay proposal at the meeting held November 10, 2025 for fiscal 2025.
Which companies are in AngioDynamics' peer group?
Companies named in the disclosed peer group include Baxter International Inc., Becton, Dickinson and Company, Boston Scientific Corporation, CONMED Corporation and DexCom, Inc., among others. Companies named in the Compensation Peer Group include Accuray Incorporated, Alphatec Holdings, Inc., Artivion, Inc., AtriCure, Inc. and AxoGen, Inc., among others.
What is AngioDynamics' chief executive pay ratio?
For fiscal 2026, the company reported a chief executive pay ratio of 45:1, against median employee compensation of $135,741.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Clemmer
President, CEO
◇—◇◇◇—◇◇
Laura Piccinini
SVP & GM, International
◇—◇◇◇—◇◇
Stephen Trowbridge
EVP, CFO
◇—◇◇◇—◇◇
Chad Campbell
SVP & GM, Vascular Access and Oncology
◇—◇◇◇—◇◇
David Helsel
SVP, Global Operations and R&D
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Clemmer
President, CEO
◇—◇◇◇—◇◇
Stephen Trowbridge
EVP, CFO
◇—◇◇◇—◇◇
Laura Piccinini
SVP & GM, International
◇—◇◇◇—◇◇
David Helsel
SVP, Global Operations and R&D
◇—◇◇◇—◇◇
Chad Campbell
SVP & GM, Vascular Access and Oncology
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Clemmer
President and Chief Executive Officer
◇—◇◇◇—◇◇
Stephen Trowbridge
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Laura Piccinini
Senior Vice President and General Manager, Cardiovascular and International
◇—◇◇◇—◇◇
Warren Nighan
Senior Vice President, Global Supply Chain, Quality and Regulatory Affairs
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Clemmer
President and Chief Executive Officer
◇—◇◇◇—◇◇
Stephen Trowbridge
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Laura Piccinini
SVP & GM, Cardiovascular and International
◇—◇◇◇—◇◇
Lawrence Weiss
Senior Vice President, Chief Legal Officer and Corporate Secretary
◇—◇◇◇—◇◇
Warren Nighan
SVP & GM, Global Supply Chain, Quality and Regulatory Affairs
◇—◇◇◇—◇◇
Fiscal 2026
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Clemmer
President, CEO
◇—◇—◇—◇◇
Stephen Trowbridge
EVP, CFO
◇—◇—◇—◇◇
Laura Piccinini
SVP & GM, Cardiovascular and International
◇—◇—◇—◇◇
Lawrence Weiss
SVP, Chief Legal Officer & Corporate Secretary
◇—◇—◇—◇◇
Warren Nighan
SVP & GM, Global Supply Chain, Quality and Regulatory Affairs
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2026
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
James C. ClemmerPSU◇◇◇—◇—◇
James C. ClemmerRSU◇——◇——◇
Laura PiccininiPSU◇◇◇—◇—◇
Laura PiccininiRSU◇——◇——◇
Lawrence T. WeissRSU◇——◇——◇
Lawrence T. WeissPSU◇◇◇—◇—◇
Stephen A. TrowbridgeRSU◇——◇——◇
Stephen A. TrowbridgePSU◇◇◇—◇—◇
Warren G. NighanPSU◇◇◇—◇—◇
Warren G. NighanRSU◇——◇——◇
Fiscal 2022, 2023, 2024, 2025 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2026 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Warren NighanOption◇—◇July 17, 2034
Option◇—◇July 19, 2033
Option◇—◇July 20, 2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Laura PiccininiOption◇—◇July 17, 2034
Option◇—◇July 19, 2033
Option◇—◇July 20, 2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Lawrence WeissOption◇—◇December 2, 2034
RSU◇◇——
PSU◇◇——
RSU◇◇——
Stephen TrowbridgeOption◇—◇July 17, 2034
Option◇—◇July 19, 2033
Option◇—◇July 20, 2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
James ClemmerOption◇—◇July 19, 2034
Option◇—◇July 17, 2034
Option◇—◇July 19, 2033
Option◇—◇July 20, 2032
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2026
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Howard W. Donnelly
Board chair
◇◇————◇
Wesley E. Johnson Jr
◇◇————◇
Jan Stern Reed
◇◇————◇
Eileen O. Auen
◇◇————◇
Lorinda A. Burgess
◇◇————◇
Karen A. Licitra
◇◇————◇
Michael E. Tarnoff
◇◇————◇
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2026
  • Baxter International Inc. BAX
  • Becton, Dickinson and Company BDX
  • Boston Scientific Corporation BSX
  • CONMED Corporation CNMD
  • DexCom, Inc. DXCM
  • Edwards Lifesciences Corporation EW
  • Enovis Corporation ENOV
  • Envista Holdings Corporation NVST
  • GE HealthCare Technologies Inc. GEHC
  • Globus Medical, Inc. GMED
  • IDEXX Laboratories, Inc. IDXX
  • InMode Ltd. INMD
  • Inogen, Inc. INGN
  • Inspire Medical Systems, Inc. INSP
  • Insulet Corporation PODD
  • Integer Holdings Corporation ITGR
  • Integra LifeSciences Holdings Corporation IART
  • Intuitive Surgical, Inc. ISRG
  • iRhythm Technologies, Inc. IRTC
  • Kewaunee Scientific Corporation KEQU
  • LivaNova PLC LIVN
  • Medtronic plc MDT
  • NovoCure Limited NVCR
  • Omnicell, Inc. OMCL
  • Penumbra, Inc. PEN
  • PROCEPT BioRobotics Corporation PRCT
  • QuidelOrtho Corporation QDEL
  • ResMed Inc. RMD
  • STERIS plc STE
  • Stryker Corporation SYK
  • Tactile Systems Technology, Inc. TCMD
  • Tandem Diabetes Care, Inc. TNDM
  • Teleflex Incorporated TFX
  • TransMedics Group, Inc. TMDX
  • Varex Imaging Corporation VREX
  • Zimmer Biomet Holdings, Inc. ZBH
Compensation Peer Group
  • Accuray Incorporated ARAY
  • Alphatec Holdings, Inc. ATEC
  • Artivion, Inc. AORT
  • AtriCure, Inc. ATRC
  • AxoGen, Inc. AXGN
  • Cutera, Inc. CUTR
  • Glaukos Corporation GKOS
  • Inari Medical, Inc. INRI
  • LeMaitre Vascular, Inc. LMAT
  • Nevro Corp. NVRO
  • Orthofix Medical Inc. OFIX
  • Orthopediatrics Corp. KIDS
  • SI-Bone, Inc. SIBN
  • STAAR Surgical Company STAA
  • Treace Medical Concepts, Inc. TMCI
  • Zynex, Inc. ZYXI

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025November 10, 2025=◇◇◇
2024November 12, 2024=◇◇◇
2023November 14, 2023=◇◇◇
2022November 3, 2022=◇◇◇
2021November 3, 2021=◇◇◇
2020October 13, 2020=◇◇◇
2019October 15, 2019=◇◇◇
2018October 10, 2018=◇◇◇
2017October 17, 2017=◇◇◇
2016October 25, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- James Clemmer (President, CEO), FY2026 total compensation $6,060,145 (base salary $828,171) [exec_comp, SEC accession 0001140361-26-039022, filed 2026-10-08]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when AngioDynamics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact AngioDynamics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where AngioDynamics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $299
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $299
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $299
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether AngioDynamics' disclosed peer group is defensible, who names AngioDynamics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
351 figures on this page: 341 cited to the filing that reported them, 10 calculated from figures it prints.
341 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001140361-26-039022
    CEO Pay Ratio · Director Compensation Table · Grants of Plan-Based Awards for Fiscal Year 2026 · Outstanding Equity Awards at Fiscal 2026 Year-End · and 1 more section
  2. 0001140361-25-041542
  3. 0001140361-24-047071
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001140361-23-053522
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001628280-23-033186
  6. 0000914121-22-004127
  7. 0001275187-22-000021
  8. 0000914121-21-007073
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0000914121-20-003700
  10. 0000914121-19-002764
  11. 0000914121-18-001946
  12. 0000914121-17-001483
  13. 0000914121-16-001612
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “AngioDynamics executive compensation, FY2022–FY2026.” https://intel.velarion.ai/comp/ANGO (accessed 2026).
Short form: data: Velarion

The paid brief for AngioDynamics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$299 for the Executive Compensation Report. Both reports for $449.
Get the executive briefGet the board briefNo account needed.
13 filings cited on this page
Method: intel.velarion.ai/methodology
If a report fails to generate we keep working until you have it. No refunds on one-time reports.
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about AngioDynamics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers AngioDynamics discloses

The companies named in ANGO's own disclosed peer group.

Baxter International Inc.Becton, Dickinson and CompanyBoston Scientific CorporationCONMED CorporationDexCom, Inc.Edwards Lifesciences CorporationEnovis CorporationEnvista Holdings CorporationGE HealthCare Technologies Inc.Globus Medical, Inc.IDEXX Laboratories, Inc.Inogen, Inc.Inspire Medical Systems, Inc.Insulet CorporationInteger Holdings CorporationIntegra LifeSciences Holdings CorporationIntuitive Surgical, Inc.iRhythm Technologies, Inc.Kewaunee Scientific CorporationLivaNova PLCMedtronic plcNovoCure LimitedOmnicell, Inc.Penumbra, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy